Bonum Therapeutics’ Post

🐁 🎙️ Check out Episode 3 of the HuMice Pubcast! Discover how Roche’s use of humanized #mousemodels drove a successful transition from preclinical discovery to a Phase 1 clinical trial. Then we dive into the humanized FcRn model used to assess human PK for calculating a safe starting dose:

📜 It's with great pride that today we release Cavenagh Health's most recent white paper on the fascinating field of RNA Therapeutics. 💉 These technologies, which have existed for decades and only after the Covid-19 pandemic managed to be validated on exciting fronts, now have the possibility of becoming an ideal modality for treating and preventing diseases. Here's the link to access the document: https://lnkd.in/e8WKZVTg 🎓 This is a document that we built with Cecilia Piergentili, PhD to summarize the state of the art of the field on several fronts: - Therapeutic modalities - Delivery options - Toxicity evaluation - Clinical Development and Regulatory Affairs-related aspects - Peculiarities of clinical trial design - Challenges ahead 🙏🏽 We want to thank Covadonga Paneda for her insights into the delivery aspects and hurdles, Nigel Horscroft for his shared thoughts on mRNAs, Thomas Thum for his contribution to a better understanding of the ncRNAs space, and Alessandro Toniolo for his insightful discussion on the interest of PE investors and current fundraising challenges. 🔎 Also, a big thank you to Mathieu Latreille, who helped us hit the nail when this was a very initial draft document. 💻 The final and visually-beautiful result is part of Indigo O'Clee and Jessica Smith from SomX. 📇 Please feel free to contact me for any comments or questions and to talk about opportunities for collaborating in this space. Hopefully, we'll be updating this initial version as the field evolves and more industrial players take assets to clinical stages! #rnatherapeutics #biotech #pharma #venturecapital #preclinical #clinicaldevelopment

A nice summary of the RNA drug development space. Worth the read and send to folks who might want to know about RNA drug potential.

🔬 Introducing Twist Precision Dx: Next-Generation Sequencing Products! These CE-marked offerings are fully compliant with EU IVDR regulations, showcasing commitment to quality and regulatory standards. Designed specifically for clinical settings, they empower whole exome sequencing with precision and reliability. Emily Leproust, CEO and co-founder of Twist Bioscience, commented, "The Twist Precision Dx products mark a significant milestone for us, representing our first NGS product line tailored for inclusion within regulated customer products. With IVDR certification in place, we're proud to offer one of the first comprehensive, fully-validated whole exome library preparation and target enrichment workflows." This initiative underscores the dedication to supporting European customers in developing clinical tests using Twist NGS tools. With multiple CE-marked products, they provide flexible solutions, including panel-agnostic library prep, exome workflows, and combined solutions for IVDR-compliant workflows. Learn more about Twist Precision Dx: https://lnkd.in/gUQVNe2N For in vitro diagnostic use. CE-mark only. Not available in all regions or countries. #Genetrics #NGS #exome #IVDR #WES #TwistBioscience #PrecisionDx

Did you take advantage of discounted access to DUBprofiler this September? Ready for the next step?   DUBprofiler-Cell and DUBprofiler-Tissue are the perfect complement to DUBprofiler, where you can profile the selectivity of your compounds in disease-relevant cell lysates, cell culture or tissue samples against endogenous DUBs.   These assays use activity-based probes (ABPs) to engage and capture active DUBs, revealing the ‘DUBome’ and demonstrating target engagement: https://rb.gy/9xc38   Please contact us if you would like to learn more, [email protected].   #DrugDiscovery #DrugDevelopment #Research #Pharma #Biotech #DUB

📢 Next webinar coming up, with yours truly and the one and only Ovidiu Novac! Join us next week to discuss the current hurdles faced within the drug discovery and development process and how Organ-on-a-chip can help! #drugdiscovery #organonchip

🌟 WEBINAR: Join us to explore the gains of supplementing your pre-clinical toolbox with organ-on-a-chip (OOC) technology.  Entitled "Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics", attend to: 🔸 Explore how OOC replicates key aspects of human organs and disease and generate mechanistic data that predicts clinical outcomes 🔸 Learn about NASH and the challenges of predicting drug safety and efficacy in humans using traditional preclinical models 🔸 Understand how our NASH model was used to explore the effect of four anti-NASH compounds, two of which are currently in clinical trials 🔸 Dscover how OOC enables you to design more predictive and cost-efficient in vivo studies that reduce animal use. 📍 Register below to join us on: Tuesday, September 26, at 3:00pm BST https://bit.ly/3PLnJUH #OrganOnChip #drugdevelopment #microphysiologicalsystem

Gene&Cell Therapy >> Merck's big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. As Reynald Castañeda, Kyle LaHucik and Lei Lei Wu bring us the latest ESMO news out of Madrid, don’t forget to sign up for our virtual event on Monday to get the experts’ take on where cancer research is now and where we are headed next. Merck’s big ADC move Merck is committing $4 billion upfront to team up with Daiichi Sankyo on a trio of antibody-drug conjugates, adding fuel to a space that’s heating up on blockbuster revenue, data readouts and a flurry of M&A. For Merck, it’s a way to “make sure we blanketed the field with the same intensity” that the company did with Keytruda, chief medical officer Eliav Barr told Endpoints. The most advanced program is slated for a BLA filing in 2024 and appears to have big potential in lung cancer, according to a trial investigator. Latest from #ESMO23 A broken embargo on the highest-profile abstracts at this year’s European Society for Medical Oncology forced the conference organizer to release data from the presentations several days early. Here’s our breakdown of the biggest datasets to watch. In one of the first presentations, Amgen detailed Phase II data for its bispecific tarlatamab in small cell lung cancer, Reynald Castañeda reports. How Eli Lilly is thinking about deals Eli Lilly is on a hot streak. Ahead of some big FDA decisions, Kyle LaHucik spoke with Lilly’s multi-hyphenated executive Dan Skovronsky about the company’s M&A plans, playing the long game in drug development and why it doesn’t need mega deals. Speaking of dealmaking, Kyle also reported that the company has agreed to acquire an antibody-drug conjugate biotech, swooping in for France-based Mablink Bioscience. AI-designed drugs face reckoning in clinic After years of hype, the first AI-designed drugs are falling short in the clinic. But executives at these first-generation companies say it’s too early for a verdict on whether or not AI boosts the odds of success, particularly given the vast likelihood that any drug candidate — AI-developed or not — will fail, Andrew Dunn writes. Q&A with Joe Jimenez Former Novartis CEO Joe Jimenez and his research right-hand, Mark Fishman, are testing a new approach to biotech investing and drug development Aditum Bio. In an interview with Kyle LaHucik, Jimenez talks about salvaging “stuck” drugs, biotech formation and why a substance abuse treatment could be worth billions of dollars. WHAT WE’RE WATCHING NEXT WEEK * Multiple major drugmakers will be reporting their… #lucidquest #genetherapy #celltherapy

If you have ever wondered about how far the therapeutic potential ADCs can reach, Philipp Spycher of Araris Biotech AG puts it this way. As long as there is an antibody to efficiently target the molecule of interest and an effective payload for it, the future of ADCs could be disease agnostic. He and two other #ADC company CEOs, Daniel J. O'Connor and Radek Spisek, gathered for a quick Q&A on the future of ADCs.